Aeglea Financial Statements From 2010 to 2024
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Check Aeglea Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aeglea Bio's main balance sheet or income statement drivers, such as , as well as many indicators such as . Aeglea financial statements analysis is a perfect complement when working with Aeglea Bio Valuation or Volatility modules.
Aeglea |
Aeglea Bio Therapeutics Company Shares Outstanding Analysis
Aeglea Bio's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Aeglea Bio Shares Outstanding | 4.05 M |
Most of Aeglea Bio's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Aeglea Bio Therapeutics has 4.05 M of shares currently outstending. This is 97.76% lower than that of the Biotechnology sector and 96.21% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.29% higher than that of the company.
Aeglea Bio Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aeglea Bio's current stock value. Our valuation model uses many indicators to compare Aeglea Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aeglea Bio competition to find correlations between indicators driving Aeglea Bio's intrinsic value. More Info.Aeglea Bio Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Aeglea Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Aeglea Bio Financial Statements
Aeglea Bio stakeholders use historical fundamental indicators, such as Aeglea Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Aeglea Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aeglea Bio's assets and liabilities are reflected in the revenues and expenses on Aeglea Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aeglea Bio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |